Journal of Oncology Pharmacy Practice

Papers
(The TQCC of Journal of Oncology Pharmacy Practice is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings60
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class39
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors28
Clinical and economic impact of pharmacist interventions in an ambulatory hematology–oncology department26
Cancer patient experience of telephone clinics implemented in light of COVID-1925
A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide24
Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab18
Factors affecting health-related quality of life among prostate cancer patients: A systematic review18
Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial17
Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations16
ISOPP Standards for the Safe Handling of Cytotoxics16
Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases15
Cisplatin-induced nephrotoxicity in children: what is the best protective strategy?15
Cryotherapy for the prevention of chemotherapy-induced peripheral neuropathy: A systematic review15
Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab15
Spine eburnation in a metastatic lung cancer patient treated with immunotherapy and radiotherapy. The first case report of bystander effect on bone14
Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review14
The prognostic values of systemic immune-inflammation index and derived neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer14
Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab13
Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature12
Practical strategies to manage cancer patients during the COVID-19 pandemic: Saudi Oncology Pharmacy Assembly Experts recommendations12
A real-world data approach to determine the optimal dosing strategy for pembrolizumab12
Impact of pharmacist-managed immune checkpoint inhibitor toxicities11
Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis11
International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care11
New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature11
Acquired Hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA vaccine, successfully treated with prednisolone and rituximab11
Incidence of hemorrhagic cystitis after cyclophosphamide therapy with or without mesna: A cohort study and comprehensive literature review11
Does nutritional status affect treatment tolarability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study11
Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer11
The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients wit11
Applications and challenges in therapeutic drug monitoring of cancer treatment: A review10
Safety of ninety-minute daratumumab infusion10
Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors10
Impact of clinical pharmacy in oncology and hematology centers: A systematic review10
Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia10
Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration10
Management of skin adverse reactions in oncology10
Global oncology pharmacy response to COVID-19 pandemic: Medication access and safety10
Surface contamination with nine antineoplastic drugs in 109 canadian centers; 10 years of a monitoring program10
Larotrectinib followed by selitrectinib in a novelDCTN1–NTRK1fusion undifferentiated pleomorphic sarcoma9
Thyroid cancer risk factors and Pakistani University students’ awareness towards its preventive practice9
Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease9
Interpersonal communication-, education- and counselling-based interventions to support adherence to oral anticancer therapy: a systematic review9
Impact of clinical pharmacy services in a hematology/oncology ward in Morocco9
Severe rhabdomyolysis induced by possible drug–drug interaction between Ribociclib and Simvastatin8
Routine antiemetic prophylaxis with dexamethasone during COVID-19: Should oncologists reconsider?8
Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation8
Global changes to the chemotherapy service during the covid-19 pandemic8
Temozolomide-induced aplastic anaemia: Case report and review of the literature8
A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy8
The safe handling of chemotherapy drugs in low- and middle-income countries: An overview of practices8
Occupational exposure assessment in professionals who manipulate and administer antineoplastic drugs in a university hospital in Southern Brazil8
A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care8
Use of active learning and simulation to teach pharmacy students order verification and patient education best practices with oral oncolytic therapies8
Ambulatory chemotherapy: Past, present, and future8
ISOPP 2023 – Abstract Book8
Lorlatinib induced proteinuria: A case report8
Anticancer agents and phytotherapy: Interactions that are often unrecognized8
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma8
Trends in the delivery of care to oncology patients in the United States: Emphasis on the role pharmacists on the healthcare team8
Prevalence of potential drug-drug interactions in breast cancer patients and determination of their risk factors8
Sensitivity and specificity of drug interaction databases to detect interactions with recently approved oral antineoplastics8
A new treatment of alopecia induced by palbociclib: Topical cetirizine8
Medication discrepancies in hospitalized cancer patients: Do we need medication reconciliation?8
Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?7
Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report7
A deep dive into CDK4/6 inhibitors: Evaluating real world toxicities and treatment paradigms in the elderly population7
The role of Bruton’s tyrosine kinase inhibitors in the management of mantle cell lymphoma7
Pembrolizumab-induced severe rejection and graft intolerance syndrome resulting in renal allograft nephrectomy7
Nivolumab treatment for metastatic thymic epithelial tumors7
Blood contamination of the pharmaceutical staff by irinotecan and its two major metabolites inside and outside a compounding unit7
Assessment of Canadian patient education material for oncology pharmaceutics7
Case report on 5-fluorouracil induced cerebrovascular accident7
Revisiting same day administration of pegfilgrastim in the age of biosimilars: A review of literature7
Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study7
Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis7
Ribociclib induced acute kidney injury: A case report7
Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab7
A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study7
Knowledge, attitude, preventive practices and perceived barriers to screening about colorectal cancer among university students of newly merged district, Kpk, Pakistan – A cross-sectional study7
Increasing pharmacy productivity and reducing medication turnaround times in an Italian comprehensive cancer center by implementing robotic chemotherapy drugs compounding6
A clinical approach to non-neutropenic fever in children with cancer6
Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer6
Unleashing the power of immunotherapy and targeted therapy combinations: Advancing cancer care or discovering unknown toxicities?6
Advanced papillary thyroid carcinoma responding to nivolumab6
Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners6
Acute cytokine release syndrome after a first dose of pembrolizumab as second-line treatment for metastatic, programmed death-ligand 1-positive, non-small-cell lung cancer6
A rare case of gastric cancer with bilateral breast metastasis during pregnancy6
Severe cisplatin-induced renal toxicity in a patient with xeroderma pigmentosum6
The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma6
Incorporating a clinical oncology pharmacist into an ambulatory care pharmacy in pediatric hematology–oncology and transplant clinic: Assessment and significance6
International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care6
Perception, knowledge, and handling practice regarding the risk of exposure to antineoplastic drugs in oncology day hospitalization units and compounding unit staff6
Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer6
Barriers and facilitators for the safe handling of antineoplastic drugs6
Ifosfamide induced encephalopathy in a child with osteosarcoma6
Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2)6
Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease6
Dosing errors in total parenteral nutrition prescriptions at a specialized cancer care hospital of Lahore: The role of clinical pharmacist6
Outcomes with enoxaparin dose reductions during thrombocytopenia in patients with hematopoietic stem cell transplantation (HSCT)6
Bluish-gray fingernail discoloration due to the use of nivolumab6
Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital6
Impact of clinical pharmacists in an inpatient medical oncology service: A prospective study at a comprehensive cancer center in Jordan6
Involvement of C677T MTHFR variant but not A1298C in methotrexate-induced toxicity in acute lymphoblastic leukemia6
Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City6
Bromocriptine for the treatment of postoperative cerebellar mutism syndrome in pediatric patients: Three case reports6
A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer6
Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: Lessons from CheckMate 9ER and IMmotion 1516
Drug-related problems and its associated factors among breast cancer patients at the University of Gondar Comprehensive Specialized Hospital, Ethiopia: A hospital-based retrospective cross-sectional s6
New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma6
Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin’s lymphoma6
Evaluation of a patient self-medication program in allogeneic hematopoietic stem cell transplantation6
Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies6
Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient6
Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma6
Non-pharmacological integrative therapies for chronic cancer pain6
Hypersensitivity reactions to paclitaxel: The Mexican experience of rapid desensitization6
Comparison of four immunoassays to an HPLC method for the therapeutic drug monitoring of methotrexate: Influence of the hydroxylated metabolite levels and impact on clinical threshold5
Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions5
Hypertriglyceridemia induced by S-1: A novel case report and review of the literature5
Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma5
Impact of anti-cancer drugs shortages in oncology and hematology departments in a Moroccan hospital5
Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 5
Glioblastoma and bevacizumab in elderly patients: Monocentric study5
Immunosuppression medication adherence after allogeneic hematopoietic stem cell transplant: Impact of a specialized clinical pharmacy program5
A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis5
Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials5
Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash5
Breastfeeding in a patient with chronic myeloid leukemia during tyrosine kinase inhibitor therapy5
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature5
Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting5
Immediate severe hypersensitivity reaction to etoposide phosphate: Case report and review of the literature5
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia5
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia5
The efficacy and safety of alpelisib in breast cancer: A real-world analysis5
Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: An ISOPP membership survey5
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma5
Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges5
Adherence to thalidomide in patients with multiple myeloma: A cross-sectional study in a Brazilian metropolis5
Fatal hepatitis B reactivation in a patient receiving chemoradiation for cervical cancer5
Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma5
The drugs screened by OncoVeeTM-Mini-PDX have significantly benefited the patient with HER2-positive advanced gastric cancer5
Two different immune related adverse events occured at pancreas after nivolumab in an advanced RCC patient5
Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant5
Sustained erythrocytosis due to the use of Lenvatinib5
A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma5
Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?5
Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report5
Evaluation of external contamination on the vial surfaces of some hazardous drugs that commonly used in Chinese hospitals and comparison between environmental contamination generated during robotic co5
Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review5
Central diabetes insipidus induced by temozolomide: A report of two cases5
Dosing of PD-1 and PD-L1 inhibitors: Cost saving initiatives for significantly decreasing associated expenditure5
Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature5
Trousseau’s syndrome in a non-small cell lung cancer patient aggravated by pembrolizumab5
Awareness is the first step: What Ghanaian community pharmacists know about cancer5
Abstracts5
Patterns of complementary and alternative medicine use among Tunisian cancer patients5
Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients5
Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies5
Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study5
Case of metastatic kaposi sarcoma successfully treated with anti-PD-1 immunotherapy5
Cyto-SAT: A self-assessment tool for the safe handling of cytotoxic drugs adapted for use in low- and middle-income countries5
Initial tacrolimus weight-based dosing strategy in allogeneic hematopoietic stem-cell transplantation5
Role of clinical pharmacist in the palliative care of adults and elderly patients with cancer: A scoping review5
Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report5
Posterior reversible encephalopathy syndrome: A rare neurotoxicity after capecitabine5
Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards4
Fluconazole-Induced adrenal insufficiency following allogeneic hematopoietic cell transplant4
Incidence of ifosfamide induced encephalopathy in patients receiving concomitant fosaprepitant4
Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists4
Novel agents for myelodysplastic syndromes4
Atypical response patterns in metastatic melanoma and renal cell carcinoma patients treated with nivolumab: A single center experience4
Tamoxifen-induced acute mania: A case report4
Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature4
Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metab4
Unmet supportive care needs and determinants among cancer patients treated at University of Gondar Specialized Hospital, Northwest Ethiopia: A prospective cross-sectional study4
Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report4
The role and economics of immunotherapy in solid tumour management4
Anti-drug antibodies anti-trastuzumab in the treatment of breast cancer4
Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer4
Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients4
Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia4
Gilteritinib administration in a hemodialysis patient4
Vascular endothelial growth factor inhibitor induced hypertension: Retrospective analysis of the impact of blood pressure elevations on outcomes4
Contribution of an anticancer drug compounding robot in reducing the risks of manual preparation in a hospital pharmacy unit specialized in oncology4
A second administration of glucarpidase in a different cycle of high-dose methotrexate: Is it safe and effective in adults?4
Adverse drug reactions associated with chemotherapeutic agents used in breast cancer: Analysis of patients’ online forums4
Hypercalcemia associated with the interaction between all trans retinoic acid and posaconazole in an acute promyelocytic leukemia case4
Suggestion of Tunisia’s medical oncologist in the management of breast cancer during COVID-19 pandemic4
Development of carpal tunnel syndrome in association with checkpoint inhibitors4
Clinical pharmacy in onco-hematology and bone marrow transplant: A valuable contribution to improving patient safety4
Clinical pharmacy services in an ambulatory oncology clinic: Patient perception and satisfaction4
Proposal of a simple and rapid method for the chemotherapy preparations analytical control by spectrophotometry UV-Vis method4
Rucaparib and olaparib for the treatment of prostate cancer: A clinician's guide to choice of therapy4
Retrospective analysis of the incidence and severity of acute kidney injury (AKI) in patients with head and neck cancer receiving weekly cisplatin with radiotherapy (RAISe-AKI)4
A review on radiation induced nausea and vomiting: “Current management strategies and prominence of radio sensitizers”4
Pemetrexed-induced Sweet Syndrome: First case report in the medical literature4
Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer4
Anaphylaxis related to disinfection with chlorhexidine in a teenager treated for cancer4
Preservation of cognitive function after brain irradiation4
Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review4
Impact of low- and high-risk operators handling irinotecan on the blood contamination of health care workers in oncology day care units4
Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion4
Papilledema and idiopathic intracranial hypertension due to the possible potentiation of ATRA by posaconazole in a case of acute promyelocytic leukemia4
Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation4
Capecitabine induced Steven–Johnson syndrome: A rare case report4
Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report4
Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer4
Monoclonal antibody extravasations: Two case reports and literature review4
Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report4
Educational needs of oncology pharmacists: A survey by the International Society of Oncology Pharmacy Practitioners4
Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations4
Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy Practice 20194
Updates on the molecular mechanisms of aspirin in the prevention of colorectal cancer: Review4
Real-world effectiveness of the pegfilgrastim on-body injector in preventing severe neutropenia4
Identification of target small molecule tyrosine kinase inhibitors that need monitoring and clinical application of protocol for early detection of cancer therapeutics-related cardiac dysfunction usin4
A pharmacist’s review of the treatment of systemic light chain amyloidosis4
Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman4
Veliparib for the treatment of solid malignancies4
Unmet supportive care needs and predictor of breast cancer patients in Bangladesh: A cross-sectional study4
Tyrosine kinase inhibitors and COVID-194
HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma4
Extemporaneous compounding and administration of tretinoin slurry for acute promyelocytic leukemia4
MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis4
Risk reduction in a cancer chemotherapy production unit: Contribution of an automated drug dispensing system4
A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners4
Risk assessment of personnel exposure in a central cytotoxic preparation unit using the FMECA method4
Evaluation and clinical impact of a pharmacist-led, interdisciplinary service focusing on education, monitoring and toxicity management of immune checkpoint inhibitors4
Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab4
Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma4
Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma4
Introduction of biosimilar pegfilgrastim in France: Economic analysis of switching from originator3
Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?3
The role of ado-trastuzumab emtansine in current clinical practice3
Dinutuximab in adult-onset chemotherapy refractory high-risk neuroblastoma3
Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma3
Impact of the implementation of a pharmacist-driven immunosuppression drug monitoring protocol for hematopoietic stem cell transplant recipients3
Perspectives toward biosimilars among oncologists: A Malaysian survey3
Acceptance of coronavirus disease 2019 vaccination by cancer patients in Cyprus: A cross-sectional study3
Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer3
Consensus Recommendations for the Safe Handling of Cytotoxic Agents in Cytotoxic Academic Research Laboratories (CARL)3
Rituximab desensitization in pediatric acute lymphoblastic leukemia with severe anaphylaxis3
Atezolizumab-induced hemolytic anemia – A case report3
Cost analysis of daratumumab therapy: Is there a cost benefit to using the recently approved subcutaneous product versus the IV product?3
Accurate determination of glomerular filtration rate in adults for carboplatin dosing: Moving beyond Cockcroft and Gault3
Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with aDPYDvariant and decreased dihydropyrimidine dehydrogenase enzyme activity3
A study to assess the impact of pharmaceutical care services to cancer patients in a tertiary care hospital3
Oncology boot camp: A preparatory curriculum for advanced pharmacy practice experience students3
Evaluation of voriconazole related adverse events in pediatric patients with hematological malignancies3
0.0971839427948